Eventide Asset Management LLC Boosts Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Eventide Asset Management LLC boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 24.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,400,000 shares of the biopharmaceutical company’s stock after purchasing an additional 1,870,904 shares during the period. Eventide Asset Management LLC owned approximately 5.10% of Nektar Therapeutics worth $12,220,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in NKTR. SG Americas Securities LLC raised its position in Nektar Therapeutics by 30.4% during the third quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 22,285 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Nektar Therapeutics during the second quarter valued at approximately $29,000. Valence8 US LP acquired a new position in Nektar Therapeutics during the third quarter valued at approximately $34,000. Intech Investment Management LLC acquired a new position in shares of Nektar Therapeutics during the third quarter worth $41,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Nektar Therapeutics by 5.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 650,841 shares of the biopharmaceutical company’s stock worth $846,000 after purchasing an additional 34,599 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on NKTR. Piper Sandler assumed coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They set an “overweight” rating and a $7.00 target price for the company. BTIG Research reaffirmed a “buy” rating and set a $4.00 price objective on shares of Nektar Therapeutics in a research note on Monday, September 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $3.50.

Nektar Therapeutics Stock Performance

Shares of NASDAQ:NKTR opened at $1.13 on Friday. Nektar Therapeutics has a 52 week low of $0.42 and a 52 week high of $1.93. The company’s fifty day moving average is $1.26 and its 200-day moving average is $1.30.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.